Rockwell Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09 2023 - 6:00AM
Business Wire
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a
healthcare company that develops, manufactures, commercializes, and
distributes a portfolio of hemodialysis products to dialysis
providers worldwide, today announced that the Compensation
Committee of the Company’s Board of Directors approved the grant of
stock options to purchase an aggregate of 30,000 shares of the
Company’s common stock to 11 new employees (the “Inducement
Grants”) on May 10, 2023 (the “Grant Date”). The Inducement Grants
have been granted outside of the Company’s 2018 Long Term Incentive
Plan (“Plan”) but remain subject to the terms and conditions of
such Plan. The Inducement Grants were granted as an inducement
material to these individuals entering into employment with
Rockwell Medical in accordance with Nasdaq Listing Rule
5635(c)(4).
The Inducement Grants have an exercise price per share that is
equal to the closing price of the Company’s common stock on the
Grant Date. The Inducement Grants will vest 25% on the first
anniversary of the Grant Date, with 1/48th of the Inducement Grant
vesting each month thereafter until fully vested, subject to
continued employment through the applicable vesting dates.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company
that develops, manufactures, commercializes, and distributes a
portfolio of hemodialysis products for dialysis providers
worldwide. Rockwell Medical's mission is to provide dialysis
clinics and the patients they serve with the highest quality
products supported by the best customer service in the industry.
Rockwell is focused on innovative, long-term growth strategies that
enhance its products, its processes, and its people, enabling the
Company to deliver exceptional value to the healthcare system and
provide a positive impact on the lives of hemodialysis patients.
Hemodialysis is the most common form of end-stage kidney disease
treatment and is typically performed at freestanding outpatient
dialysis centers, hospital-based outpatient centers, skilled
nursing facilities, or in a patient’s home. Rockwell Medical's
products are vital to vulnerable patients with end-stage kidney
disease, and the Company is relentless in providing unmatched
reliability and customer service. Rockwell Medical is the second
largest supplier of acid and bicarbonate concentrates for dialysis
patients in the United States and intends to become the leading
global supplier of hemodialysis concentrates. Certified as a Great
Place to Work® in 2023, Rockwell Medical is Driven to Deliver
Life-Sustaining Dialysis SolutionsTM. For more information, visit
www.RockwellMed.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230809836805/en/
Heather R. Hunter SVP, Chief Corporate Affairs Officer (248)
432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2024 to May 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From May 2023 to May 2024